SFE Investment Counsel Purchases 2,548 Shares of Intuitive Surgical, Inc. $ISRG

SFE Investment Counsel grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 105.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 4,957 shares of the medical equipment provider’s stock after purchasing an additional 2,548 shares during the quarter. SFE Investment Counsel’s holdings in Intuitive Surgical were worth $2,016,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ISRG. Stevens Capital Partners raised its holdings in Intuitive Surgical by 9.9% in the 3rd quarter. Stevens Capital Partners now owns 686 shares of the medical equipment provider’s stock valued at $279,000 after acquiring an additional 62 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of Intuitive Surgical by 3.4% during the third quarter. ProShare Advisors LLC now owns 398,808 shares of the medical equipment provider’s stock worth $162,167,000 after purchasing an additional 12,952 shares during the last quarter. Vise Technologies Inc. boosted its holdings in shares of Intuitive Surgical by 43.7% during the third quarter. Vise Technologies Inc. now owns 20,025 shares of the medical equipment provider’s stock worth $8,143,000 after purchasing an additional 6,087 shares during the last quarter. Investment Partners LTD. boosted its holdings in shares of Intuitive Surgical by 105.9% during the third quarter. Investment Partners LTD. now owns 2,854 shares of the medical equipment provider’s stock worth $1,161,000 after purchasing an additional 1,468 shares during the last quarter. Finally, Cidel Asset Management Inc. purchased a new stake in shares of Intuitive Surgical in the third quarter valued at $216,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ISRG. TD Cowen reissued a “buy” rating and issued a $485.00 price target on shares of Intuitive Surgical in a research note on Monday, October 19th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Intuitive Surgical in a research note on Wednesday, August 12th. Robert W. Baird increased their price objective on shares of Intuitive Surgical from $513.00 to $550.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. KeyCorp reissued an “overweight” rating on shares of Intuitive Surgical in a research report on Wednesday, August 12th. Finally, JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $450.00 to $475.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $493.54.

Intuitive Surgical Trading Down 3.7%

Shares of ISRG opened at $432.01 on Friday. The firm has a market capitalization of $149.75 billion, a P/E ratio of 52.24, a price-to-earnings-growth ratio of 2.98 and a beta of 1.46. The stock’s fifty day simple moving average is $401.54 and its 200 day simple moving average is $434.05. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The firm had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same quarter last year, the firm earned $2.40 earnings per share. The firm’s revenue for the quarter was up 21.7% compared to the same quarter last year. Sell-side analysts predict that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,150 shares of the business’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $443.80, for a total transaction of $510,370.00. Following the completion of the sale, the director owned 1,150 shares in the company, valued at approximately $510,370. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 4,047 shares of the business’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $453.21, for a total value of $1,834,140.87. Following the sale, the vice president owned 1,026 shares of the company’s stock, valued at $464,993.46. The trade was a 79.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 38,778 shares of company stock valued at $16,814,967 over the last three months. Insiders own 0.60% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.